

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A planned interim analysis of the CLL11 trial by an independent data monitoring committee indicated that obinutuzumab/chlorambucil significantly improved progression-free survival compared to rituximab/chlorambucil for patients with previously untreated CLL.
 - a. True
 - b. False

2. Which of the following agents is classified as a BTK inhibitor?
 - a. AVL-292
 - b. Ibrutinib
 - c. Idelalisib
 - d. Both a and b
 - e. Both a and c
 - f. All of the above

3. Brentuximab vedotin is an antibody-drug conjugate that targets _____.
 - a. CD20
 - b. CD30
 - c. CD5

4. Data from the pivotal trial that led to the approval of brentuximab vedotin in the treatment of HL after failure of ASCT reported a response rate exceeding 70% for patients undergoing treatment in this setting.
 - a. True
 - b. False

5. Which of the following statements is true with regard to the results of the Phase II BELIEF trial of single-agent belinostat for patients with relapsed or refractory PTCL?
 - a. Incidence of thrombocytopenia with belinostat seemed to be attenuated versus rates reported with other HDAC inhibitors evaluated in PTCL
 - b. The activity of belinostat was higher in patients with angioimmunoblastic T-cell lymphoma compared to the overall patient population
 - c. Both a and b
 - d. Neither a nor b

6. A Phase II trial published by Scholz and colleagues evaluating _____ as first-line therapy for patients with FL reported high response rates (56% complete response and 31% partial response) with this agent.
 - a. ⁹⁰Yttrium-ibritumomab tiuxetan
 - b. ¹³¹I-tositumomab
 - c. R-CHOP

7. What is the mechanism of action of alisertib (MLN8237)?
 - a. Antimetabolite
 - b. Alkylating agent
 - c. Aurora A kinase inhibitor
 - d. None of the above

8. The Phase III ECHELON-2 trial is evaluating _____ in combination with CHP versus CHOP as first-line therapy for patients with CD30-positive mature T-cell lymphomas.
 - a. Brentuximab vedotin
 - b. Pralatrexate
 - c. Romidepsin
 - d. All of the above

9. The Phase II ECOG-E2408 trial is evaluating BR with or without _____ followed by rituximab with or without lenalidomide for patients with high-risk FL.
 - a. Bortezomib
 - b. Carfilzomib
 - c. Both of the above

10. Preliminary analyses of data from studies evaluating lenalidomide for patients with relapsed/refractory DLBCL suggest that this agent has significantly more activity in which of the following DLBCL subtypes?
 - a. Activated B-cell DLBCL
 - b. Germinal center B-cell DLBCL
 - c. Neither of the above